関連する実験動画
Updated: Feb 20, 2026

08:53
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
821
活性炭の使用によるフィブリノゲン検査におけるビヴァリルジンの干渉を解決する
Jia Du1,2, Haiyan Liu1, Xiaohui Liu1,2
1Clinical Laboratory, Wuhan Asia General Hospital Affiliate to Wuhan University of Science and Technology, Wuhan, China.
Journal of clinical laboratory analysis
|February 18, 2026
まとめ
ビヴァリルジンのような直接トロンビン阻害剤は,偽りの低フィブリノゲン結果を引き起こす可能性があります. 活性炭はビヴァリルジンを効果的に除去し,フィブリノゲンアッセイにおけるその干渉を解決します.
科学分野:
- 臨床化学 臨床化学について
- 血液学 ヘマトロジ
- バイオケミストリー バイオケミストリー
背景:
- 直接トロンビン阻害剤 (DTIs) は,実験室での測定に干渉することがあります.
- ビバリルジンのフィブリノゲン検査への影響は,徹底的な調査を必要としています.
- フィブリノゲンの正確な測定は,患者の管理に不可欠です.
研究 の 目的:
- フィブリノゲンアッセイにおけるビヴァリルジンの干渉を評価する.
- この干渉を緩和する活性炭の有効性を評価する.
主な方法:
- 血のサンプルには,異なる濃度のビヴァリルジンを添加した.
- フィブリノゲン濃度は,クラウスアッセイと免疫アッセイを用いて測定された.
- 活性化部分血小板形成時間 (APTT) とフィブリノゲンは,活性炭処理前と後の分析を行った.
主要な成果:
- 免疫測定では,ビヴァリルジンによる干渉は示されなかった.
- クラウスアッセイでは,フィブリノゲン結果の濃度に依存した有意な減少が示されました.
- 活性炭はビヴァリルジンを効果的に除去し,フィブリノゲンのレベルをベースラインに戻した.
結論:
- フィブリノゲンアッセイにおけるビヴァリルジンの干渉はアッセイに依存する.
- 活性炭は,ビヴァリルジンの干渉を排除する有効な方法です.
- この発見は,ビヴァリルジンの治療を受けている患者におけるフィブリノゲン検査の正確さを裏付けている.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
392
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
392
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Clot Retraction and Fibrinolysis
9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
Coagulation
1.5K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.5K

